The Synergistic and Attenuated Mechanism of Action of the Xihuang Pill in Dual Immunotherapy After Stenting for Advanced Cholangiocarcinoma: A Controlled Clinical Trial.

PURPOSE

This study aims to investigate the synergistic and attenuation mechanism of Xihuang pill in the treatment of cholangiocarcinoma (CCA), thereby providing a reliable scientific basis for the selection of postoperative treatment strategies in cholangiocarcinoma patients.

METHODS

In total, 120 patients with advanced CCA who underwent stent implantation were divided into control group I (n = 40), control group II (n = 40), and observation group (n = 40). The patients in control group I were only treated with a tumor immunosuppressant (tislelizumab injection), the patients in control group II were administered tumor double immunotherapy (tislelizumab injection + thymalfasin injection), and the patients in the observation group were treated with Xihuang pill combined with tumor double immunotherapy. The therapeutic effect, side effects, coagulation function, tumor markers, and immune function were compared among the three groups.

RESULTS

Compared to the patients in control groups I and II, those in the observation group showed significantly longer activated partial thromboplastin time (APPT) and prothrombin time (PT), and lower fibrinogen (FIB) levels and platelet count (PLT) after treatment (P < 0.05). In the observation group, the levels of CD3+, CD4+, and CD4+/CD8+ increased, but the level of CD8+ decreased. The levels of CEA, CA125, CA19-9, CA242, and CA50 in serum decreased. The adverse reactions in the observation group were lower, while the objective remission rate (ORR) was significantly higher than their corresponding values in control groups I and II (42.5%vs17.5%, 27.5%) (P < 0.05). The 1-year overall survival rates of the control group I, control group II and observation group were 42.5%, 50% and 60%, and the difference was not statistically significant (P > 0.05).

CONCLUSION

Xihuang Pill combined with dual immunotherapy can synergistically enhance anti-tumor efficacy and reduce treatment-related toxicity in patients with advanced CCA by regulating coagulation function and immune mechanisms.